1,725 件 ・ 関連度順
概要と使いどころ
Assess the reliability of companies and individuals through Openapi Risk - credit scores, CRIF reports, patrimonial reports, negative events, heirs reports, worldwide KYC (PEP, sanction lists, adverse media). Use for due diligence, creditworthiness, AML/KYC questions.
日本語の概要は準備中です。原文の説明を表示しています。
Comprehensive guide to designing reliable, scalable data systems covering databases, streaming, and consistency
日本語の概要は準備中です。原文の説明を表示しています。
Application of Six Sigma quality methodology to AI agent process improvement and reliability
日本語の概要は準備中です。原文の説明を表示しています。
Apply rapport-based elicitation to resistant or semi-cooperative humans and agents. Use when coercive prompting or brittle handoffs damage cooperation. NOT for routine cooperative tasks, pure technical debugging, or already reliable exchanges.
日本語の概要は準備中です。原文の説明を表示しています。
Framework for coordinating meaning across autonomous agents that use different conceptual models, vocabularies, and knowledge representations. Treats ontologies as first-class negotiable resources rather than hardcoded implementation details.
日本語の概要は準備中です。原文の説明を表示しています。
Detects fabricated content, false citations, and unverifiable claims in agent outputs. Uses source verification and consistency checking. Activate on 'detect hallucination', 'fact check', 'verify claims', 'check accuracy', 'find fabrications'. NOT for validation (use dag-output-validator) or confidence scoring (use dag-confidence-scorer).
日本語の概要は準備中です。原文の説明を表示しています。
Diagnose when intuitive judgment, agent confidence, or expert routing can be trusted by classifying environment validity, feedback quality, and task-boundary fit. Use for confidence calibration, agent routing, expertise audits, and escalation design. NOT for deterministic implementation tasks, pure syntax debugging, or domains with explicit verifiable answers.
日本語の概要は準備中です。原文の説明を表示しています。
Safety, privacy, cost management, and frank advice for building always-on AI agents with episodic memory. Covers data hygiene, privacy risk surfaces, runaway cost prevention, scope creep, psychological effects of persistent AI companions, and responsible deployment patterns. This is the skill that tells you what can go wrong and how to prevent it. Activate on: "agent safety", "always-on agent privacy", "agent cost control", "persistent agent risks", "AI companion safety", "agent data hygiene", "runaway agent costs", "parasocial AI risk", "/always-on-agent-safety". NOT for: architecture design (use always-on-agent-architecture), input design (use always-on-agent-inputs), application brainstorming (use always-on-agent-applications), healthcare compliance specifically (use hipaa-compliance).
日本語の概要は準備中です。原文の説明を表示しています。
Aligns sample metadata with count matrices and constructs design matrices for downstream DE, handling the alphabetical-reference-level trap (relevel BEFORE DESeq), LRT reduced-model rules, the interaction-term resultsNames trap, continuous-covariate scaling and splines, repeated measures via duplicateCorrelation or dream, high-cardinality categorical pseudo-singular designs, sample swap detection via XIST/RPS4Y1 expression and somalier/NGSCheckMate genotypes, SABV (sex-as-biological-variable) mandate, Simpson's-paradox collapsing of technical replicates, and the `~ 0 + group` parameterization for clean contrasts. Use when building a design matrix, troubleshooting reversed fold-change direction, encoding paired or repeated-measures designs, detecting sample swaps, deciding sex-as-covariate, or aggregating technical replicates.
日本語の概要は準備中です。原文の説明を表示しています。
Handles batch effects in bulk RNA-seq via design-matrix inclusion (the correct path for DE), ComBat/ComBat-seq for visualization, SVA for unknown latent factors, RUVSeq for negative-control-gene-anchored unwanted variation, and limma::removeBatchEffect for plotting only. Encodes the Nygaard 2016 cardinal sin against testing on a batch-corrected matrix, the choice between SVA/RUVg/RUVs/RUVr, the confounding non-identifiability problem, the single-cell boundary (Harmony/MNN are NOT for bulk), and the Goh 2017 harmonization critique. Use when designing a DE analysis with batch structure, troubleshooting batch-dominated PCA, choosing ComBat vs ComBat-seq, handling unknown batch via SVA, integrating across studies, or deciding when (rarely) to subtract batch.
日本語の概要は準備中です。原文の説明を表示しています。
Infer integer allele-specific copy number, tumor purity, and ploidy from tumor sequencing by jointly modeling read depth (logR) and B-allele frequency (BAF) with ASCAT, Sequenza, FACETS, PURPLE, and PureCN (tumor-only). Covers the purity-ploidy identifiability problem, the diploid-baseline (dipLogR) anchor, major/minor copy number, loss of heterozygosity, sunrise/contour fit diagnostics, and reconciliation of conflicting fits. Use when tumor analysis needs absolute copy number rather than relative log2, when estimating purity and ploidy, calling LOH or copy-neutral LOH, resolving whole-genome doubling, running tumor-only allele-specific calling, or choosing among ASCAT, Sequenza, FACETS, and PureCN.
日本語の概要は準備中です。原文の説明を表示しています。
Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Estimate causal effects of an exposure on an outcome from GWAS summary statistics using genetic instruments. Implements IVW (fixed/random), MR-Egger, weighted median/mode, MR-RAPS, CAUSE, GSMR-HEIDI, MR-PRESSO, MVMR, MR-Clust, LCV, and LHC-MR via TwoSampleMR, MendelianRandomization, MR-PRESSO, cause, and lhcMR. Use when testing causal direction between traits, evaluating drug-target effects via cis-pQTL/cis-eQTL, performing multivariable mediation MR, distinguishing causation from correlated horizontal pleiotropy, or producing STROBE-MR-compliant sensitivity batteries.
日本語の概要は準備中です。原文の説明を表示しています。
Analyze TF motif accessibility variability across samples or single cells using chromVAR. Use when identifying TF motifs whose accessibility correlates with conditions, computing per-sample motif z-scores after matched background correction, comparing to ArchR / Signac equivalents, or distinguishing motif-accessibility signal from per-site footprinting.
日本語の概要は準備中です。原文の説明を表示しています。
Trim multiple sequence alignments using ClipKIT, trimAl, BMGE, Divvier, or HMMcleaner with mode selection guidance per downstream goal. Use when removing unreliable columns or contaminating residues before phylogenetic inference, HMM building, or selection analysis.
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests using real-time continuous glucose monitoring (CGM) and algorithm-driven insulin pumps (ADIPs) rather than multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG) three or more times daily for adults and children with type 1 diabetes (T1D). Trigger phrases include "Should I use RT-CGM+ADIP or MDI+SMBG for this T1D patient?" or "Is intensive pump therapy indicated for this patient?"
日本語の概要は準備中です。原文の説明を表示しています。
Recommends RT-CGM devices for adult patients with well-controlled type 1 diabetes who are willing and able to use the devices on a nearly daily basis. Trigger phrases include 'Controlled T1DM patient interested in CGM' and 'Consider RT-CGM for glycemic stability in well-controlled T1DM'.
日本語の概要は準備中です。原文の説明を表示しています。
Assess whether a hospitalized adult with diabetes on insulin pump therapy remains a candidate for continued inpatient pump use. Consider triggers such as the clinician asking "Is this patient appropriate to continue insulin pump in hospital?" and evaluate for impaired consciousness, inability to adjust pump settings, critical illness, DKA, or hyperosmolar hyperglycemic state.
日本語の概要は準備中です。原文の説明を表示しています。
Suggests real-time CGM over no CGM for outpatients with type 2 diabetes who use insulin and/or sulfonylureas and are at high risk for hypoglycemia to detect and prevent low glucose events. Consider when initiating CGM in T2D patients on insulin/SU with a history of severe hypoglycemia or impaired awareness of hypoglycemia (IAH).
日本語の概要は準備中です。原文の説明を表示しています。
This skill determines whether testicular volume should be used as the primary or sole indicator of sexual development in male childhood cancer survivors who have received gonadotoxic treatments such as alkylating agents or testicular radiotherapy. Triggers include clinician questions like “Can I use testicular volume to assess puberty in this male survivor after chemotherapy?” or “Is testis size reliable for sexual maturity evaluation post‑radiation?”
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests using real-time continuous glucose monitoring (CGM) rather than no CGM for outpatients with type 2 diabetes (T2D) who take insulin and/or sulfonylureas and are at high risk for hypoglycemia. It is triggered by clinician questions such as "Should I use CGM for this T2D patient on insulin or sulfonylureas with high hypoglycemia risk?" or "Is CGM indicated for this patient?"
日本語の概要は準備中です。原文の説明を表示しています。
Recommends CGM over SMBG for type 1 diabetes patients on multiple daily injections to reduce hypoglycemia risk. Triggered by clinician questions such as "Should I use CGM or SMBG for this T1D patient on MDI?" or "Is CGM preferred for glucose monitoring in this patient?"
日本語の概要は準備中です。原文の説明を表示しています。
Suggests short-term, intermittent real-time CGM use in adult patients with type 2 diabetes not on prandial insulin who have A1C ≥7% and are willing and able to use the device. Triggered by phrases such as “T2DM basal-only, A1C ≥7%, consider intermittent CGM” or “Short-term CGM for non-prandial T2DM with elevated A1C”.
日本語の概要は準備中です。原文の説明を表示しています。
Evaluates cardiovascular risk factors in persons receiving hormone therapy by obtaining fasting lipid profiles and diabetes screening. Triggered when a patient is on gender-affirming hormone therapy and due for routine cardiovascular risk assessment.
日本語の概要は準備中です。原文の説明を表示しています。